Human Trials

ViiV Healthcare begins study on implementation of once-monthly injectable HIV treatment

ViiV Healthcare has commenced a trial to identify and assess approaches for implementing its once-monthly injectable treatment for HIV into clinical practice.

Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer

Ipsen and Servier announced preliminary data from the Phase 1/2 study of the investigational use of liposomal irinotecan (ONIVYDE) in combination with 5- fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in study patients with previously untreated metastatic pancreatic ductal adenocarcinoma cancer (PDAC) at the ESMO 21st World Congress on Gastrointestinal Cancer in Barcelona, Spain, 3–6 July 2019.

BiondVax enrols first patient in phase 3 second cohort of M-001 flu vaccine

BiondVax Pharmaceuticals said that it has enrolled the first participant in the second cohort of a phase 3 trial of its M-001 universal flu vaccine candidate.

Pfizer, Sangamo’s gene therapy show promise in phase 1/2 hemophilia A study

Pfizer and Sangamo Therapeutics have announced that an investigational SB-525 hemophilia A gene therapy has showed a sustained increased factor VIII (FVIII) levels in phase 1/2 Alta study.

VALBIOTIS announces positive results from phase IIA trial of VALEDIA in prediabetics

VALBIOTIS announced positive results (topline data) for the Phase IIA study of VALEDIA (active substance: TOTUM-63), which evaluated this product's efficacy in a prediabetic population, compared to placebo.

Cantargia announces full recruitment of CAN04 monotherapy arm in ongoing phase IIa clinical trial

Cantargia´s antibody CAN04 (nidanilimab) is investigated in an open label three-armed phase IIa clinical trial, CANFOUR.

GSK begins phase 3 trial for otilimab in patients with rheumatoid arthritis

GSK today announced the start of a phase III clinical development programme with otilimab, an investigational anti-granulocyte macrophage colony-stimulating factor (anti GM-CSF) monoclonal antibody, for patients with moderate to severe rheumatoid arthritis (RA) who have had an inadequate response to disease modifying antirheumatic drugs (DMARD) or targeted therapies.

Roche’s flu drug Xofluza meets primary endpoint in phase III children study

Roche’s flu drug Xofluza (baloxavir marboxil) has achieved primary endpoint in phase III Ministone-2 children study.

Dicerna to begin clinical development of DCR-A1AT for A1AT deficiency-associated liver disease

Dicerna Pharmaceuticals has submitted a Clinical Trial Authorization (CTA) application to the Swedish Medical Products Agency (MPA) last week to conduct a first-in-human Phase 1/2 study of DCR-A1AT, an investigational therapy from the Company’s GalXC technology platform, for the treatment of alpha-1 antitrypsin (A1AT) deficiency-associated liver disease.